Core Viewpoint - BioLife Solutions, Inc. is a prominent player in the cell and gene therapy market, focusing on the development and supply of cell processing tools and services [2]. Group 1: Company Overview - BioLife Solutions specializes in providing solutions that ensure the health and functionality of biological materials throughout their lifecycle, including collection, development, manufacturing, and distribution [2]. - The company is publicly traded on Nasdaq under the ticker symbol BLFS [1]. Group 2: Earnings Call Information - BioLife Solutions has announced corrected call-in numbers for their upcoming Earnings Call scheduled for May 8, 2025, at 4:30 PM ET [1]. - The call-in number for participants in the United States is 1-833-630-0431, while international participants can dial 1-412-317-1808 [1].

Core Insights - BioLife Solutions, Inc. has appointed Cathy Coste to its board of directors, increasing the total board membership to seven [1] - Ms. Coste will serve as chair of the audit committee, succeeding Joydeep Goswami, who will remain a director and member of the audit committee [1] Company Overview - BioLife Solutions is a leading developer and supplier of bioproduction tools and services specifically for the cell and gene therapy (CGT) market [4] - The company focuses on maintaining the health and function of biologic materials during their collection, development, storage, and distribution [4] Leadership and Expertise - Cathy Coste brings over four decades of experience as a senior executive, with a strong background in audits, risk and controls, and compliance [2] - She has worked with more than two dozen life sciences companies during her tenure at Deloitte and has extensive experience in governance initiatives and strategic planning [2][3] - Ms. Coste has served as a director and audit committee chair for multiple companies, including Biomerica, Inc., Minerva Surgical, Inc., and Renalytix plc [3] Future Outlook - Ms. Coste expressed optimism about BioLife's position for revenue growth and sustained profitability following its transition to a pure-play enabler of cell and gene therapies [2]